Comparison of Myo-inositol Versus Metformin for Treating Obesity in Patients With Polycystic Ovarian Syndrome
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- Reduction in body mass index
研究概览
简要总结
There are considerable gaps in the comparative effectiveness and tolerability of myo-inositol and metformin for treating obesity in patients with polycystic ovarian syndrome (PCOS). The current study aimed to give insights comparing myo-inositol versus metformin for treating obesity in patients with PCOS.
详细描述
A review of the literature reveals inconsistent outcomes of myo-inositol vs metformin in the treatment of obesity and metabolic disorders in patients with PCOS, with comparable results and myo-inositol frequently demonstrating superior tolerability and reduced gastrointestinal side effects relative to metformin. When treating obesity in women with PCOS, practicing gynecologists would be able to select more appropriate medications by gathering data from local contexts. It will lessen psychological consequences associated with obesity, such as discrimination, stigma, low self-esteem, and poor quality of life.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Females aged 18-45 years
- •Diagnosed case of PCOS for more than 6 months of duration
排除标准
- •Women with hyperprolactinemia or hypothyroidism (on history & medical record review)
- •Adrenal hyperplasia or Cushing's syndrome (on history & medical record review)
研究组 & 干预措施
Group-A
Women were given tablet myo-inositol 1 gm twice a day for 3 months.
干预措施: Myo-inositol (Drug)
Group-B
Women received metformin 250 mg three times daily for 3 months.
干预措施: Metformin (Drug)
结局指标
主要结局
Reduction in body mass index
时间窗: 3 months
A reduction in the body mass index with respect to baseline was taken as efficacy of the treatment.
次要结局
未报告次要终点
研究者
Muhammad Aamir Latif
Research Consultant
RESnTEC, Institute of Research